研究者詳細 - 望月　眞弓

論文 - 望月　眞弓

分割表示 102 件中 1 - 20 件目／全件表示 >>

薬局における脂質測定の機会提供の有用性に関する探索的研究

丸山順也,中原佐彩,,富永佳子,多田紀夫,望月眞弓

日本臨床栄養学会雑誌（日本臨床栄養学会） 42 （ 2 ） 179 - 190 2021年06月

研究論文（学術雑誌）, 共著

Effect of a lever aid on hand strength required for using a handheld inhaler correctly

Nakada H., Aomori T., Mochizuki M.

International Journal of Pharmaceutics （International Journal of Pharmaceutics） 596 2021年03月

ISSN 03785173

In the treatment of asthma and chronic obstructive pulmonary disease, using a lever aid to improve drug delivery from an inhaler is recommended for patients with poor muscle strength. However, no studies have investigated the effect on hand strength of using a lever aid. Here, we measured hand strength before and after operating a lever aid and tried to predict the required strength. We compared the pinch force required to activate a pressurized metered dose inhaler (pMDI) and a dry powder inhaler as well as the rotational torque required to activate a soft mist inhaler (SMI) before and after attaching a lever aid. We then assessed the correlation between the theoretical and measured pinch force after fitting the lever aid. Use of the lever aid significantly reduced the pinch force required for pMDI operation from 26.13–48.74 N to 4.90–16.87 N. In contrast, using a lever aid significantly reduced the force needed to rotate SMI, although the rotational torque required to operate did not change. There was a significant positive correlation between the theoretical and measured pinch forces required to activate a pMDI fitted with a lever aid. Using a lever aid will increase the number of patients who can use this device.

Access to Document (DOI)

A cross-sectional study clarifying profiles of patients with diabetes who discontinued pharmacotherapy: reasons and consequences

Tominaga Y., Morisky D.E., Mochizuki M.

BMC Endocrine Disorders （BMC Endocrine Disorders） 21 （ 1 ） 117 - 124 2021年

研究論文（学術雑誌）, 共著, 査読有り

Background: Although diabetes is one of the fastest increasing diseases in prevalence worldwide and demands significant medical resources, more than half of all patients with diabetes do not achieve the expected target level of blood glucose. As a potential cause of poor glycemic control, insufficient adherence to medication has long been discussed and variably studied. However, dropout from treatment as another plausible cause has not been fully examined. The aim of this study was to clarify profiles of patients with diabetes who discontinued pharmacotherapy (Discont group) by extracting reasons of their decisions and by comparing with those who continued (Cont group) in terms of the related factors to glycemic control. Methods: A cross-sectional, internet-based survey was conducted among Japanese with diabetes registered in a database. A self-administered questionnaire consisting of the 8-item version of the Morisky Medication Adherence Scale (MMAS-8), glycosylated haemoglobin (HbA1c) level, and demographic and disease characteristics was completed by all participants. Reasons for medication discontinuation and resumption were also received retrospectively from participants in the Discont group. To examine the risk of uncontrolled HbA1c, logistic regression analysis was conducted in each group. Results: In the Discont group (148 cases), older age at resumption of pharmacotherapy and current smoking habit increased the probability of uncontrolled HbA1c, whereas in the Cont group (146 cases), a familial history of diabetes and better medication adherence in MMAS-8 scores decreased the probability of uncontrolled HbA1c. A relationship between medication adherence and HbA1c level was seen in the Cont but not in the Discont group. About 70 % of those in the Discont group made their decision to terminate diabetes treatment without consulting physicians and half of them perceived their situations inappropriately. Conclusions: Those who discontinued pharmacotherapy were less adherent to medication than those who did not discontinue. Risk factors for glycemic control also differed between those who discontinued and those who did not. More than one-third of participants with diabetes who discontinued pharmacotherapy had inappropriate perceptions of their disease, which medical professionals should be aware of for better interventions.

Access to Document (DOI)

Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: An approach using latent class analysis

Anzai T., Takahashi K., Watanabe M., Mochizuki M., Murashima A.

BMC Psychiatry （BMC Psychiatry） 20 （ 1 ） 2020年03月

© 2020 The Author(s). Background: Little is known regarding the association between adverse events (AEs) and psychiatric medications administered to pregnant women in clinical trials during the pre-marketing period. This study analyzes reports of AE association with psychiatric medication administrated during pregnancy using post-marketing spontaneous reports of AE from the Japanese Adverse Drug Event Report (JADER) database and Food and Drug Administration Adverse Event Reporting System in the United States (FAERS-US). Methods: We summarized AE reports of psychiatric medication administrated during pregnancy by comparing data obtained from JADER and FAERS-US databases with medication patterns determined as classes via latent class analysis. The odds ratios (ORs) of AE reports categorized into system organ classes in which each class was compared with those without psychiatric medications. Results: The proportions of AE reports under psychiatric medication in pregnancy among all AE reports were 22.0% and 16.6% in JADER and FAERS-US, respectively. The 10,389 reports of psychiatric medication during pregnancy were classified into 11 classes. The proportion of patients receiving four or more psychiatric drugs in JADER was larger than that in FAERS-US. The maximum number of reports in combinations of AE and medication pattern in JADER was 169, for 'general disorders and administration site conditions' from the class of four or more medications (OR = 9.1), while that in FAERS-US was 1,654, for 'injury, poisoning, and procedural complications' from the class of single psychiatric medication (OR = 2.8). Conclusions: The main AE reports and associated AE differed depending on medication patterns in pregnant women taking psychiatric medication. This study may provide a prediction of AEs that are likely to be reported with each medication pattern. Our findings of the association between AE reports and medication patterns could help improve the administration of psychiatric medications during pregnancy, though further research on additional datasets is needed to clarify these results.

Access to Document (DOI)

Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics 

Matsuoka K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Nagauma M., Kanai T., Mochizuki M., Hashiguchi M.

International journal of clinical pharmacology and therapeutics （International journal of clinical pharmacology and therapeutics） 58 （ 2 ） 89 - 102 2020年02月

ISSN 09461965

OBJECTIVE: Crohn's disease (CD) is a chronic inflammatory gastrointestinal disease with repeated cycles of exacerbation and remission. Infliximab (IFX), a chimeric anti-TNF-α monoclonal antibody, has been widely used for the treatment of CD. However, no study in Japanese CD patients receiving continuous IFX for more than 1 year has been reported. To avoid therapeutic failure during long-term administration in Japanese CD patients, we evaluated the variable factors of IFX pharmacokinetics and the optimal trough IFX concentration at 8 weeks after administration. MATERIALS AND METHODS: Population pharmacokinetic (PPK) analysis was performed using the nonlinear mixed-effect model based on the IFX serum concentration in 832 samples from 121 patients. A one-compartment model was used to examine interindividual variability in the systemic clearance (CL) of intravenously administered IFX. RESULTS: PPK estimates (estimated value, RSE%) were total clearance (CL: 0.018 L/h, 9.1) and volumes of distribution (Vd: 7.35 L, 12.0). Interindividual variability for CL and Vd of 0.11 and 0.16, respectively, was found. Body weight, antibody to IFX (ATI), and albumin level were factors affecting the IFX CL. IFX CL was greater in the ATI-positive than in the ATI-negative group. CL was also greater in nonremission patients. There was a significant association between the predicted serum IFX trough concentration at 8 weeks and therapeutic response with long-term continuous administration (p < 0.05), with a higher concentration at 8 weeks seen in the remission group. CONCLUSION: Using these variables including body weight, ATI, and albumin level, the IFX dose could be calculated for individual CD patients to achieve the optimal therapeutic range.

Access to Document (DOI)

Exploration of education and research on drug informatics

Mochizuki M.

Yakugaku Zasshi （Yakugaku Zasshi） 140 （ 4 ） 543 - 554 2020年

ISSN 00316903

© 2020 The Pharmaceutical Society of Japan I have been exploring methods for education and research on drug information for 43 years. There are various approaches to drug informatics research, which include collecting, evaluating, and analyzing information to solve drug related problems, sometimes producing new information from experiments and clinical research. All are based on information science. Drug informatics is information science from the viewpoint of pharmaceuticals. In addition to basic pharmacology, knowledge and skills such as epidemiology, data science, computer science, mathematical statistics, and communication studies are indispensable for the development of drug informatics.

Access to Document (DOI)

Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine

Akiyama S., Matsuoka K., Fukuda K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Naganuma M., Motobayashi M., Suzuki K., Takenaka K., Fujii T., Saito E., Nagahori M., Ohtsuka K., Mochizuki M., Watanabe M., Hashiguchi M., Kanai T.

Journal of Gastroenterology and Hepatology (Australia) （Journal of Gastroenterology and Hepatology (Australia)） 34 （ 10 ） 1751 - 1757 2019年10月

ISSN 08159319

© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd Background and Aim: A missense variant of the nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) gene (R139C) predisposes Asian patients with inflammatory bowel disease (IBD) to thiopurine-induced leukopenia. This study evaluates the long-term effect of NUDT15 R139C heterozygosity on hematological parameters during thiopurine administration. Methods: We enrolled 83 Japanese IBD patients who were on anti-tumor necrosis factor-α agents and had used thiopurine. NUDT15 R139C was genotyped by polymerase chain reaction. We retrospectively reviewed patient clinical charts to collect data on white blood cell (WBC) count, mean corpuscular volume (MCV), hemoglobin, and platelet count during the 24 months following thiopurine initiation. Results: The included patients had either Crohn's disease (54; 65.1%) or ulcerative colitis (29; 34.9%). Genotyping of NUDT15 R139C identified 62 patients (74.7%) of genotype C/C and 21 (25.3%) of genotype C/T. The median dose of thiopurine was lower in the C/T group than in the C/C group after starting thiopurine. At 6 months, the mean WBC count of the C/T group became significantly lower than that of the C/C group (P = 0.008) and remained lower through the 24 months. The C/T group developed grade 2–4 leukopenia by 6 months, which persisted through 12–24 months. The mean MCV in the C/T group became higher than that of the C/C group after 3 months. Conclusions: NUDT15 R139C heterozygosity affected the WBC count and MCV for 24 months after thiopurine administration. Our results indicate that careful monitoring of leukopenia and dose adjustment are necessary throughout treatment in IBD patients heterozygous for the NUDT15 R139C.

Access to Document (DOI)

Positive predictive value of ICD-10 codes for acute myocardial infarction in Japan: A validation study at a single center

Ando T., Ooba N., Mochizuki M., Koide D., Kimura K., Lee S., Setoguchi S., Kubota K.

BMC Health Services Research （BMC Health Services Research） 18 （ 1 ） 2018年11月

© 2018 The Author(s). Background: In Japan, several large healthcare databases have become available for research since the early 2000's. However, validation studies to examine the accuracy of these databases remain scarce. We conducted a validation study in order to estimate the positive predictive value (PPV) of local or ICD-10 codes for acute myocardial infarction (AMI) in Japanese claims. In particular, we examined whether the PPV differs between claims in the Diagnosis Procedure Combination case mix scheme (DPC claims) and in non-DPC claims. Methods: We selected a random sample of 200 patients from all patients hospitalized at a large tertiary-care university hospital between January 1, 2009 and December 31, 2011 who had an inpatient claim assigned a local or ICD-10 code for AMI. We used a standardized data abstraction form to collect the relevant information from an electronic medical records system. Abstracted information was then categorized by a single cardiologist as being either definite or not having AMI. Results: In a random sample of 200 patients, the average age was 67.7 years and the proportion of males was 78.0%. The PPV of the local or ICD-10 code for AMI was 82.5% in this sample of 200 patients. Further, of 178 patients who had an ICD-10 code for AMI based on any of the 7 types of condition codes in the DPC claims, the PPV was 89.3%, whereas of the 161 patients who had an ICD-10 code for AMI based on any of 3 major types of condition codes in the DPC claims, the PPV was 93.8%. Conclusion: The PPV of the local or ICD-10 code for AMI was high for inpatient claims in Japan. The PPV was even higher for the ICD-10 code for AMI for those patients who received AMI care through the DPC case mix scheme. The current study was conducted in a single center, suggesting that a multi-center study involving different types of hospitals is needed in the future. The accuracy of condition codes for DPC claims in Japan may also be worth examining for conditions other than AMI such as stroke.

Access to Document (DOI)

Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease

Matsuoka K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Naganuma M., Kanai T., Mochizuki M., Hashiguchi M.

PLoS ONE （PLoS ONE） 13 （ 10 ） 2018年10月

研究論文（学術雑誌）, 共著, 査読有り, ISSN 1932-6203

© 2018 Hsieh et al. Since anti-tumor necrosis factor (TNF)-α agents (TNF-α inhibitors) induce both clinical response and remission in patients with moderate to severe inflammatory bowel disease (IBD), the use of anti-TNF therapies has fundamentally changed the approach to treatment for patients with IBD. Infliximab (IFX) is a TNF-α inhibitor approved for the induction and remission of Crohn's disease (CD). However, even among patients who initially demonstrate a clinical response to IFX therapy, secondary loss of response occurs, although the reason remains unknown. We therefore investigated predictive factors associated with the response to IFX in long-term maintenance treatment in Japanese CD patients. Eight types of single-nucleotide polymorphisms (SNPs) were investigated using the real-time PCR method, and patient characteristics were collected from the electronic medical records. The Crohn's Disease Activity Index criteria were used as the response to IFX therapy. The observation period was 1 year after IFX had been administered for more than 1 year. Associations between the IFX response and patient characteristics were evaluated using the multivariate logistic regression model. We studied 121 unrelated adult Japanese with CD treated for more than 1 year with IFX as outpatients at Keio University Hospital from November 1, 2014 to November 30, 2015. Among them, 71 were classified as in remisson. In multivariate analysis, patients with the TNF-α 857C>T C/C genotype, shorter disease duration, without double dosing, and combination treatment with an immunomodulator had higher remisson rates than those with the C/T or T/T genotype, longer disease duration, with double dosing, and no combination treatment with an immunomodulator. The response to IFX in Japanese CD patients may therefore be predicted by these 4 characteristics in actual clinical practice.

Access to Document (DOI)

Factors predicting the therapeutic response to methotrexate in Japanese patients with rheumatoid arthritis: A hospital-based cohort study

Hakamata J., Kaneko Y., Shimizu M., Yamaoka K., Maruyama J., Takeuchi T., Mochizuki M., Hashiguchi M.

Biological and Pharmaceutical Bulletin （Biological and Pharmaceutical Bulletin） 41 （ 9 ） 1414 - 1422 2018年09月

研究論文（学術雑誌）, 共著, 査読有り, ISSN 0918-6158

© 2018 The Pharmaceutical Society of Japan. Methotrexate (MTX) is used widely as a first-line drug for the treatment of rheumatoid arthritis (RA) worldwide. There are large interindividual differences in the therapeutic response to MTX, but it is not known which factors influence them. We therefore investigated predictive factors associated with the therapeutic response to MTX in a hospital-based cohort study. Japanese adult RA outpatients prescribed MTX were enrolled and their characteristics were collected from the electronic medical records. The European League Against Rheumatism (EULAR) response criteria were used as the response to MTX therapy. The observation period was 1 year after beginning MTX administration. Sixteen types of single-nucleotide polymorphisms were investigated using the real-time PCR method. Associations between the MTX response and patient characteristics were evaluated using the multivariate logistic regression model. Among 70 Japanese adult RA outpatients, 52 were classified as MTX responders. In multivariate analysis, patients with the solute carrier family 19 member 1 (SLC19A1) 80G>A A/A genotype had a better response than those with the A/G or G/G genotype, and patients with the C allele of γ-glutamyl hydrolase (GGH) 16T>C had a better response than those with the T/T genotype.This study showed that the therapeutic response to MTX in Japanese RA patients was associated with the genetic polymorphisms of SLC19A1 80G>A and GGH 16T>C in actual clinical practice.

Access to Document (DOI)

Extraction and standardization of patient complaints from electronic medication histories for pharmacovigilance: Natural language processing analysis in Japanese

Usui M., Aramaki E., Iwao T., Wakamiya S., Sakamoto T., Mochizuki M.

Journal of Medical Internet Research （Journal of Medical Internet Research） 20 （ 9 ） 2018年09月

© Misa Usui, Eiji Aramaki, Tomohide Iwao, Shoko Wakamiya, Tohru Sakamoto, Mayumi Mochizuki. Originally published in JMIR Medical Informatics (http://medinform.jmir.org), 27.09.2018. This is an open-access article distributed under the terms of the Creative Commons Attribution License. Background: Despite the growing number of studies using natural language processing for pharmacovigilance, there are few reports on manipulating free text patient information in Japanese. Objective: This study aimed to establish a method of extracting and standardizing patient complaints from electronic medication histories accumulated in a Japanese community pharmacy for the detection of possible adverse drug event (ADE) signals. Methods: Subjective information included in electronic medication history data provided by a Japanese pharmacy operating in Hiroshima, Japan from September 1, 2015 to August 31, 2016, was used as patients' complaints. We formulated search rules based on morphological analysis and daily (nonmedical) speech and developed a system that automatically executes the search rules and annotates free text data with International Classification of Diseases, Tenth Revision (ICD-10) codes. The performance of the system was evaluated through comparisons with data manually annotated by health care workers for a data set of 5000 complaints. Results: Of 5000 complaints, the system annotated 2236 complaints with ICD-10 codes, whereas health care workers annotated 2348 statements. There was a match in the annotation of 1480 complaints between the system and manual work. System performance was .66 regarding precision, .63 in recall, and .65 for the F-measure. Conclusions: Our results suggest that the system may be helpful in extracting and standardizing patients' speech related to symptoms from massive amounts of free text data, replacing manual work. After improving the extraction accuracy, we expect to utilize this system to detect signals of possible ADEs from patients' complaints in the future.

Access to Document (DOI)

Exploratory evaluation of a commercially available Japanese medical record database as an external control for comparative clinical trials in new drug development: Amyotrophic lateral sclerosis

Fukamachi S, Hashiguchi M, Takahashi K, Mochizuki M

Neurology and Clinical Neuroscience （Japanese Society of Neurology and John Wiley & Sons Australia, Ltd） 6 94 - 99 2018年05月

研究論文（学術雑誌）, 共著, 査読有り

Access to Document (DOI)

OTC医薬品添付文書におけるピクトグラム表示の試み

朴京子, 小山慎一, 山下純, 望月眞弓, 日比野治雄

医薬品情報学（日本医薬品情報学会） 20 （ 1 ） 20 - 28 2018年05月

研究論文（学術雑誌）, 共著, 査読有り

Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan .

Hashiguchi M, Hakamata J, Shimizu M, Maruyama J, Shiga T, Mochizuki M.

Int J Clin Pharmacol Ther. 2018年04月

研究論文（学術雑誌）, 共著, 査読有り

Access to Document (DOI)

Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: A hospital based-cohort study

Hakamata J., Hashiguchi M., Kaneko Y., Yamaoka K., Shimizu M., Maruyama J., Takeuchi T., Mochizuki M.

Modern Rheumatology （Modern Rheumatology） 2 （ 4 ） 1 - 10 2018年01月

研究論文（学術雑誌）, 共著, ISSN 14397595

© 2017, © 2017 Japan College of Rheumatology. Objectives: Methotrexate (MTX) is used as first-line treatment of rheumatoid arthritis (RA) worldwide. Large interindividual differences in MTX effectiveness and safety occur, and the most frequent adverse reaction is hepatotoxicity, although the main cause remains unknown. We investigated factors associated with MTX-induced hepatic enzyme elevation in a hospital-based cohort study. Methods: Study participants were 114 Japanese adult RA outpatients prescribed MTX. Sixteen types of single-nucleotide polymorphisms were investigated using real-time PCR. Patient characteristics were collected from the electronic medical records. The onset of MTX-induced abnormal hepatic enzyme elevation was defined according to deviation from normal liver enzyme reference values during treatment. The observation period was 1 year after beginning MTX. Associations between MTX-induced hepatic enzyme elevation and patient characteristics were evaluated using the multivariate logistic regression model. Results: Thirty-two patients experienced MTX-induced abnormal hepatic enzyme elevation. In multivariate analysis, MTX dosage, estimated glomerular filtration rate (eGFR), and genetic polymorphisms of ABCB1 3435C>T and ATIC 347C>G were associated with abnormal hepatic enzyme elevation. Conclusions: MTX-induced abnormal hepatic enzyme elevation in Japanese RA patients was associated with dosage and eGFR as nongenetic factors, and with ABCB1 3435C>T and ATIC 347C>G as genetic factors in this hospital-based cohort study.

Access to Document (DOI)

Possible associations of personality traits representing harm avoidance and self-directedness with medication adherence in Japanese patients with type 2 diabetes.

Y. Tominaga, T. Aomori, T. Hayakawa, N. Kijima, D.E. Morisky, K. Takahashi, M. Mochizuki.

Journal of Pharmaceutical Health Care and Sciences. 4 16 2018年

研究論文（学術雑誌）, 共著, 査読有り

Relationship between medication adherence and glycemic control in Japanese patients with type 2 diabetes

Tominaga Y., Aomori T., Hayakawa T., Morisky D., Takahashi K., Mochizuki M.

Pharmazie （Pharmazie） 73 （ 10 ） 609 - 612 2018年

ISSN 00317144

© 2018 Govi-Verlag Pharmazeutischer Verlag GmbH. All rights reserved. A cross-sectional survey of 358 patients was conducted among type 2 diabetes patients recruited at medical institutions or via an online research company. Medication adherence was measured using the 8-item Morisky Medication Adherence Scale (MMAS-8). Univariate and multivariate regression analyses of glycosylated hemoglobin (HbA 1c ) were performed in addition to assessing demographic and disease characteristics and MMAS-8. In conclusion, medication adherence as measured by the MMAS-8 score independently contributes to altering the HbA 1c level in the range of 1.12 %. The number of medications prescribed and insulin use are also related to HbA 1c .

Access to Document (DOI)

Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan

Hashiguchi M., Hakamata J., Shimizu M., Maruyama J., Shiga T., Mochizuki M.

International Journal of Clinical Pharmacology and Therapeutics （International Journal of Clinical Pharmacology and Therapeutics） 56 （ 7 ） 310 - 320 2018年

ISSN 09461965

©2018 Dustri-Verlag Dr. K. Feistle. Objective: To investigate quantitatively the risk factors for rhabdomyolysis or related symptoms associated with HMG-CoA reductase inhibitors (statins), we used the lipid-lowering drug database (32,157 patients) developed by the RAD-AR Council, Japan, based on the postmarketing surveillance (PMS) data of pharmaceutical companies to perform a nested case-control study. Materials and methods: Of 26,849 patients taking statins, the case group was composed of 51 patients who experienced rhabdomyolysis or related symptoms while taking statins, and the control group was 1,020 patients randomly selected from patients who did not experience rhabdomyolysis or related symptoms while taking statins. Relevant factors that can be extracted from the database were: sex, age, body mass index (BMI), statin use duration, complications, concomitant medication, and clinical laboratory test values. Results: Among those taking statins, 51 experienced rhabdomyolysis or related symptoms. Factors differing significantly between the two groups by univariate analysis were age, duration of statin intake, combination drugs (Ca antagonists, angiotensin II receptor blocker (ARB), cardiac drugs, benzodiazepines, mucoprotective drugs, insulin, α-glucosidase inhibitors), clinical laboratory results (high-density lipoprotein cholesterol (HDL-C), aspartate aminotransferase, alkaline phosphatase, total bilirubin), and complications (alcoholic hepatitis). Conditional multivariate logistic analysis of these factors yielded adjusted/odds ratios of 8.82 for the concomitant administration of an ARB and 3.45 for increased AST and 3.20 for increased total bilirubin levels. Conclusion: Risk factors for rhabdomyolysis or related symptoms associated with taking statins were combination with ARB and increases in AST or total bilirubin levels.

Access to Document (DOI)

Risk factors for hyperuricemia with HMG-CoA reductase inhibitors using a postmarketing surveillance database in Japan

Hashiguchi M., Hakamata J., Shimizu M., Maruyama J., Shiga T., Mochizuki M.

Japanese Journal of Clinical Pharmacology and Therapeutics （Japanese Journal of Clinical Pharmacology and Therapeutics） 49 （ 4 ） 145 - 150 2018年

ISSN 03881601

Copyright: © 2018 the Japanese Society of Clinical Pharmacology and Therapeutics(JSCPT) Background: Little is known about whether HMG-CoA reductase inhibitor(statin)treatment exerts an adverse effect on serum levels of uric acid. It remains unknown whether statin use is associated with an increased risk of hyperuricemia. The purpose of this study was to identify the risk factors for developing hyperuricemia or blood uric acid elevation associated with statin use utilizing the Japanese RAD-AR postmarketing surveillance database. Methods: We performed a nested case-control study using a postmarketing surveillance database in Japan. The database cohort included 26,914 cases of statin use in patients with hyperlipidemia. Participants received at least one type of statin, had a clear medication history of statin use, and no complication of hyperuricemia. Cases were defined as onset of hyperuricemia or blood uric acid elevation during statin intake. For each case, 20 controls were randomly selected and matched by time-point. The factors associated with an increased risk of hyperuricemia or blood uric acid elevation during statin intake examined included sex, age, body mass index, statin use duration, complications, concomitant medications, and clinical laboratory test values. Statin-associated hyperuricemia or blood uric acid elevation was identified based on abnormal elevation of blood uric acid concentrations beyond the reference range. Results: A total of 20,783 patients met the inclusion criteria, of whom 23 were in the case group. Two complicating factors, sympathetic inhibitory antihypertensive drugs (adjusted odds ratio［OR］: 4.22)and triglyceride level(adjusted OR: 2.48), were extracted for onset of hyperuricemia or blood uric acid elevation. Conclusion: This study suggested that the onset of hyperuricemia or blood uric acid elevation might increase with statin use in patients with complications of hypertriglyceridemia and concomitant administration of sympathetic inhibitory antihypertensive drugs.

Access to Document (DOI)

Effect of everolimus on the glucose metabolic pathway in mouse skeletal muscle cells (C2C12)

Kayoko Yoshida, Chiyo K. Imamura ,Kanako Hara ,Mayumi Mochizuki, Yusuke Tanigawara

Metabolomics （Cross Mard） 13 98 2017年07月

研究論文（学術雑誌）, 共著, 査読有り

Access to Document (DOI)

　前のページ - 次のページ　

望月 眞弓

論文 - 望月 眞弓

望月　眞弓

論文 - 望月　眞弓